Kate L McCarty, Angelo L Gaffo, Cesar Diaz-Torne
8 min
Gout is a prevalent and painful inflammatory arthritis driven by the deposition of monosodium urate crystals in joint spaces. Despite its high morbidity and the availability of effective pharmacological treatments, clinical management remains suboptimal. Worldwide, fewer than half of patients receive definitive care, and medication adherence is notably low. Effective management requires a dual approach: long-term control of serum urate levels and the immediate, rapid treatment of painful gout flares.
Modern rheumatology consensus emphasizes a treat-to-target approach, which aims to reduce serum urate below the solubility threshold to ensure crystal dissolution. For most patients, this means reaching and sustaining a serum urate level of 6 mg/dL or lower, with a more stringent target of 5 mg/dL recommended for those with severe tophaceous disease. Initiation of urate-lowering therapy (ULT) should not be delayed by the presence of an active flare, as current evidence shows that early initiation does not worsen the flare. A critical component of this strategy is the mandatory inclusion of anti-inflammatory prophylaxis for the first 3–6 months of ULT to mitigate the risk of triggering new flares as crystal stores dissolve.
Pharmacological management is divided into urate-lowering agents and acute flare therapy. Xanthine oxidase inhibitors, such as allopurinol, remain the primary first-line choice for long-term management. For cases requiring alternatives, uricosurics and uricase therapies are available. When managing acute flares, clinicians prioritize NSAIDs, colchicine, or glucocorticoids, carefully selecting agents based on the patient's existing comorbidities, such as chronic kidney disease or cardiovascular history. Emerging therapies, including newer IL-1 antagonists, offer viable alternatives for patients who cannot tolerate or do not respond to traditional first-line anti-inflammatory medications.
Improving gout care requires moving beyond simple symptom management. Multidisciplinary models—such as nurse-led clinics that prioritize patient education and consistent monitoring—have demonstrated significant success in improving adherence and achieving target urate levels. Because gout is frequently comorbid with metabolic syndromes and carries an increased cardiovascular risk, integrating systemic health management into the gout care plan is essential for long-term patient well-being.
Gout is a common and painful inflammatory arthritis caused by monosodium urate crystal deposition into joints in the setting of hyperuricemia. Recent reports indicate an increase in prevalence and incidence of gout worldwide. While genetics, dietary habits, and lifestyle play a significant role in the development of gout, risk factors also include diabetes, hypertension, obesity, chronic kidney disease, and metabolic disease among others. As such, accompanying comorbidities must also be considered when choosing therapeutic agents for urate-lowering therapy (ULT) and gout flares. This article will focus on reviewing gout pathophysiology and discussion of currently available pharmacological and nonpharmacological options for chronic gout management, gout flare therapy, and prophylactic measures. Despite an increase in prevalence, optimal gout management remains elusive and challenging with only a third to half of patients receiving definitive treatment and fewer than half of patients remaining adherent to treatment. Current strategies for optimal chronic gout management include the “treat to target” method, which focuses on targeting serum urate level of 5–6 mg/dL or lower. Additional approaches for chronic gout management include starting ULTs with 3–6 months of prophylaxis to reduce the risk of precipitating gout flares during initiation. Both improvement of the recognition and diagnosis of gout and more widespread provider adherence to international rheumatology society recommendations for gout management remain barriers to optimal gout management worldwide. This article will also serve as a review of current urate-lowering pharmacological options including xanthine oxidase inhibitors, uricosurics, and uricase therapy as well as burgeoning new medications on the horizon including novel potent xanthine oxidase inhibitors (including tigulixostat), sodium-glucose transporter-2 inhibitors, and selective URAT1 inhibitors. Additionally, this article will review pharmacological approaches to treating gout flares (including nonsteroidal anti-inflammatory drugs, glucocorticoids, and colchicine) and discuss the role of patient comorbidities in selection of optimal therapy. The present review will also discuss the role and limitations of novel interleukin-1 (IL-1) antagonists (including anakinra and canakinumab) in the treatment of gout flares. Lastly, this article will also discuss nonpharmacological intervention for gout management and discuss novel therapies for chronic gout management, gout flare, and prophylaxis on the horizon.
Sam: It cites growing evidence linking sustained target-level reduction with fewer attacks, smaller or fewer tophi, and improved quality of life. It also cites lower mortality, but does not provide enough study detail here to unpack that claim. This is a treatment synthesis, not a new trial with one population and one effect estimate.
Alex: So we can follow the argument, but cannot judge every benefit’s size from this article alone. Where does its practical reasoning become most concrete?
Sam: Allopurinol, a medicine that reduces urate production, is the clearest example. It is the preferred treatment for most patients. The strategy is to start at a low dose, then increase gradually according to measured urate, rather than leave everyone on the same dose.
Alex: Kidney disease often makes clinicians cautious about medication. Does the review treat it as a reason to abandon dose increases?
Sam: No. It distinguishes a cautious starting dose from a permanently low maintenance dose. Patients with kidney disease need particular care at initiation because of serious hypersensitivity risk. But the review says subsequent increases can be made safely to reach the target, including in patients with substantial kidney impairment.
Alex: That distinction also changes how we compare drugs. A fixed dose might make one medicine look better simply because the other was never adjusted.
Sam: The review makes that point with febuxostat, another medicine that reduces urate production. It outperformed a fixed allopurinol dose in lowering urate. But the authors report no difference when both drugs are compared using dose titration. Treatment strategy matters alongside drug selection.
Alex: Febuxostat also has a cardiovascular safety debate. Does this review settle that?
Sam: It describes conflicting trial findings. The CARES trial raised concern about cardiovascular risk compared with allopurinol. The later FAST trial, alongside limitations of CARES, supported a more reassuring interpretation. The review does not reproduce enough trial-level detail for us to resolve that disagreement independently.
Alex: Another concern is that starting long-term treatment can itself trigger an attack. How do the authors handle that apparent contradiction?
Sam: They recommend temporary anti-inflammatory prophylaxis, meaning preventive treatment against attacks, while urate-lowering treatment begins. The recommended period is at least three to six months. That early flare risk does not mean the long-term strategy has failed.
Alex: Does someone already having an attack still need to wait before starting treatment to lower urate?
Sam: The review challenges that traditional advice. It cites studies finding that starting during an attack does not increase its intensity or duration. Timing should depend on the individual patient, rather than a blanket rule to wait. That is a practice update, not a new finding generated by these authors.
Alex: For the attack itself, having several effective drugs is useful only if we can choose among them. What organizes that choice?
Sam: The patient’s other conditions. Standard options are nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticoids, or steroids. Anti-inflammatory drugs can worsen kidney function, fluid retention, and bleeding risk. Steroids can worsen blood sugar, making diabetes relevant. Colchicine also needs attention to kidney function and interacting medicines.
Alex: Is there a comparison that shows why more treatment is not necessarily better treatment?
Sam: The review summarizes a trial comparing low-dose colchicine with high-dose treatment and placebo. Low-dose treatment provided similar pain control to high-dose treatment, with fewer side effects. But the review does not give the trial’s sample size or absolute response rates, limiting how closely we can assess that comparison here.
Alex: What about newer treatments for patients who cannot use those standard options?
Sam: Some block interleukin-one, an inflammatory signal involved in crystal-triggered attacks. The review describes evidence supporting them when standard treatments are unsuitable or ineffective. But infection risk, high cost, and limited access constrain their use. Other emerging medicines aim to reduce urate production or increase its removal; several remain investigational.
Alex: Lifestyle advice is another major part of gout care. Does this review position diet as an alternative to medication?
Sam: No. Diet and weight management can help, especially given associated cardiovascular and metabolic risks. But dietary changes generally lower urate only modestly, often insufficiently as sole treatment. The authors also warn against blaming patients: genetics matter, and demanding lifestyle changes can distract from effective medication.
Alex: That leaves an implementation problem, not just a drug-development problem. How large is the treatment gap?
Sam: The review reports that only a third to half of patients receive definitive urate-lowering treatment. Fewer than half remain adherent. It also describes improved outcomes with nurse-led and multidisciplinary care. My reading is that better delivery of established treatment is central to the article, alongside its discussion of new medicines.
Alex: Who should read the full review, and where should they begin?
Sam: Clinicians and researchers connecting gout with kidney disease, diabetes, or cardiovascular care should read it. Start with “Urate Lowering Therapies,” especially the target-based approach and dose-titration discussion. Then read the flare-treatment sections relevant to those overlapping conditions. Use it as a clinical map; consult the cited studies for effect sizes and disputed safety questions. For everyone else, remember: relieving the attack is not the same as removing its cause.
Alex: Keep that distinction in mind.